3.70
Solid Biosciences Inc stock is traded at $3.70, with a volume of 2.11M.
It is down -14.35% in the last 24 hours and down -33.81% over the past month.
See More
Previous Close:
$4.32
Open:
$3.91
24h Volume:
2.11M
Relative Volume:
0.94
Market Cap:
$370.42M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.2171
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-22.59%
1M Performance:
-33.81%
6M Performance:
-46.92%
1Y Performance:
-72.22%
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SLDB
Solid Biosciences Inc
|
3.70 | 370.42M | 14.79M | -102.44M | -91.73M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-08-25 | Initiated | Truist | Buy |
Dec-13-24 | Initiated | Wedbush | Outperform |
Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
May-31-24 | Resumed | Piper Sandler | Overweight |
Mar-28-24 | Initiated | William Blair | Outperform |
Mar-15-24 | Initiated | Citigroup | Buy |
Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-08-23 | Initiated | H.C. Wainwright | Buy |
Jul-12-21 | Initiated | Piper Sandler | Neutral |
May-27-21 | Initiated | Jefferies | Buy |
Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-09-21 | Initiated | Barclays | Overweight |
Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-11-19 | Initiated | Evercore ISI | Outperform |
Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
May-14-19 | Downgrade | Goldman | Neutral → Sell |
Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-06-18 | Initiated | Citigroup | Sell |
Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey
Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India
Solid Biosciences director Kahn Clare buys $9,924 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update - Defense World
Q1 EPS Forecast for Solid Biosciences Boosted by Analyst - Defense World
Top 10 Insider Purchases Last Month - Insider Monkey
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire
Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan
Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World
HC Wainwright Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
Solid Biosciences shares leap on raised price target to $20 By Investing.com - Investing.com Canada
Solid Biosciences price target raised to $20 from $16 at H.C. Wainwright - TipRanks
FY2026 Earnings Forecast for SLDB Issued By William Blair - Defense World
Chardan Capital Reaffirms “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
SLDB Stock Rallies 60% in a Month: Here's What You Should Know - MSN
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade - Yahoo Finance
Solid Biosciences Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Solid Biosciences stock target holds at $15 on therapy optimism - Investing.com
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating - TipRanks
Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating - TipRanks
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Solid Biosciences Inc. (SLDB) reports earnings - Quartz
Solid Biosciences reports Q4 EPS ($1.00), consensus (78c) - TipRanks
Solid Biosciences Reports Positive Data from Duchenne Gene Therapy Trial and Provides Business Update - Nasdaq
Solid Biosciences Inc. SEC 10-K Report - TradingView
SLDBSolid Bioscience Latest Stock News & Market Updates - Stock Titan
Duchenne Patient Stories - Solid Biosciences
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Genetic Medicine Developer Solid Biosciences Sets March Conference Schedule: What's Coming? - StockTitan
Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
How Solid Biosciences Uses Equity Compensation to Attract New Talent - StockTitan
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
3 Reasons to Sell CSL and 1 Stock to Buy Instead - The Globe and Mail
Solid Biosciences Inc. (SLDB) Latest Stock News & Headlines - Yahoo Canada Finance
Leerink Partnrs Issues Optimistic Outlook for SLDB Earnings - MarketBeat
Solid Biosciences Inc.'s (NASDAQ:SLDB) stock price dropped 11% last week; individual investors would not be happy - Yahoo Finance
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. - The Globe and Mail
What is Chardan Capital's Forecast for SLDB FY2025 Earnings? - MarketBeat
Solid Biosciences Inc [SLDB] stock for 4,030,000 USD was bought by Bain Capital Life Sciences Inv - Knox Daily
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):